Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Opsumit
Pharma
FDA signs off on Merck’s potential blockbuster Winrevair for PAH
With the FDA’s approval of Winrevair to treat pulmonary arterial hypertension, Merck is set to launch the first disease-modifying treatment for PAH.
Kevin Dunleavy
Mar 26, 2024 5:11pm
FDA approves Johnson & Johnson's combo pill Opsynvi for PAH
Mar 25, 2024 11:05am
J&J dumps Opsumit trial upon pulmonary hypertension flop
Sep 7, 2023 11:03am
In PAH patients, J&J's combo pill Opsynvi increases blood flow
Mar 6, 2023 9:37am
Remicade and Xarelto woes haven't stopped J&J hiking forecast
Apr 17, 2018 12:19pm
Actelion's Opsumit fails key study as J&J megadeal nears
Jan 23, 2017 9:13am
